Indication

Treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs. Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.

Medicine details

Medicine name:
tofacitinib (Xeljanz)
SMC ID:
SMC2422
Pharmaceutical company
Pfizer Ltd
Submission type
Abbreviated
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC